Pub Date : 2025-10-01Epub Date: 2025-03-04DOI: 10.1016/j.rbmo.2025.104874
Rossella Fucci, Patrizia Falcone, Francesco Capodanno, Sara Rubini, Andrea Gallinelli, Vincenzo Lofiego, Silvia De Stefani, Mariangela Primiterra, Elisabetta Coccia, Elisabetta Baldi, Simone Palini
Research question: What effect does the use of a rapid warming method of vitrified embryos have on survival and pregnancy?
Design: A comparison of two different warming embryos protocols: long protocol (group 1, n = 486) and a new fast protocol (group 2, n = 413) for blastocyst and cleavage stage frozen embryo transfers at two IVF centres: Assisted Reproductive Technology Centre, Careggi University Hospital Firenze and IVF Unit, 'Cervesi' Hospital Cattolica. Total pregnancy rate was considered primary outcome, and embryo survival rate, clinical pregnancy rate, miscarriage rate, ongoing pregnancy rate and mean time required for warming procedure were considered secondary outcomes.
Results: The same embryo survival rate was observed in the two groups. Total and clinical pregnancy rates seemed to be higher, but not statistically different, in group 2 compared with group 1 (29.5% versus 26.7% and 27.6% versus 22.6%, respectively). Conversely, a statistically significant reduction in miscarriage rate was found in group 2 compared with group 1 (18.0% versus 32.3%, P = 0.009). Similarly, a significant increase in pregnancy rate at 26 gestational weeks or over was observed in group 2 compared with group 1 (66.9% versus 80.3%, P = 0.016). Finally, a difference in time required for warming procedures was found in favour of group 2.
Conclusions: The use of the fast warming protocol is a valid alternative to the classic warming protocol, and allows a reduction in the time needed to carry out the procedure and the workload of embryologists in an IVF laboratory.
研究问题:使用玻璃化胚胎的快速加热方法对存活和怀孕有什么影响?设计:比较两种不同的加热胚胎方案:在两个体外受精中心(辅助生殖技术中心,佛罗伦萨Careggi大学医院和卡托利卡Cervesi医院体外受精部)进行囊胚和卵分裂期冷冻胚胎移植的长方案(第1组, = 486)和新的快速方案(第2组, = 413)。总妊娠率被认为是主要结局,胚胎存活率、临床妊娠率、流产率、持续妊娠率和平均升温所需时间被认为是次要结局。结果:两组胚胎存活率相同。2组总妊娠率和临床妊娠率似乎高于1组,但无统计学差异(分别为29.5%比26.7%和27.6%比22.6%)。相反,与1组相比,2组流产率明显降低(18.0% vs 32.3%, P = 0.009)。同样,与1组相比,2组26孕周及以上的妊娠率显著增加(66.9% vs 80.3%, P = 0.016)。最后,发现加热程序所需的时间差异有利于第2组。结论:使用快速升温方案是经典升温方案的有效替代方案,并且可以减少执行程序所需的时间和体外受精实验室胚胎学家的工作量。
{"title":"Do faster, do better: frozen embryo transfer outcomes with one-step warming protocol at different embryos stages.","authors":"Rossella Fucci, Patrizia Falcone, Francesco Capodanno, Sara Rubini, Andrea Gallinelli, Vincenzo Lofiego, Silvia De Stefani, Mariangela Primiterra, Elisabetta Coccia, Elisabetta Baldi, Simone Palini","doi":"10.1016/j.rbmo.2025.104874","DOIUrl":"10.1016/j.rbmo.2025.104874","url":null,"abstract":"<p><strong>Research question: </strong>What effect does the use of a rapid warming method of vitrified embryos have on survival and pregnancy?</p><p><strong>Design: </strong>A comparison of two different warming embryos protocols: long protocol (group 1, n = 486) and a new fast protocol (group 2, n = 413) for blastocyst and cleavage stage frozen embryo transfers at two IVF centres: Assisted Reproductive Technology Centre, Careggi University Hospital Firenze and IVF Unit, 'Cervesi' Hospital Cattolica. Total pregnancy rate was considered primary outcome, and embryo survival rate, clinical pregnancy rate, miscarriage rate, ongoing pregnancy rate and mean time required for warming procedure were considered secondary outcomes.</p><p><strong>Results: </strong>The same embryo survival rate was observed in the two groups. Total and clinical pregnancy rates seemed to be higher, but not statistically different, in group 2 compared with group 1 (29.5% versus 26.7% and 27.6% versus 22.6%, respectively). Conversely, a statistically significant reduction in miscarriage rate was found in group 2 compared with group 1 (18.0% versus 32.3%, P = 0.009). Similarly, a significant increase in pregnancy rate at 26 gestational weeks or over was observed in group 2 compared with group 1 (66.9% versus 80.3%, P = 0.016). Finally, a difference in time required for warming procedures was found in favour of group 2.</p><p><strong>Conclusions: </strong>The use of the fast warming protocol is a valid alternative to the classic warming protocol, and allows a reduction in the time needed to carry out the procedure and the workload of embryologists in an IVF laboratory.</p>","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"51 4","pages":"104874"},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Research question: What are the experiences, needs and preferences of women with a history of sexual trauma undergoing fertility treatment?
Design: Women survivors of sexual violence who were previously referred for, underwent or were undergoing fertility treatment were invited to participate in an online survey. Respondents were asked about which screening tool they preferred to gather information about the history of sexual violence, and to rate the significance of specific triggers related to fertility treatment.
Results: A total of 155 women responded to the survey. The preferred screening tool for a history of sexual violence was an intake form (76 women [63%]) followed by direct questioning (20 women [16.5%]). Only 11 women (9%) preferred not to be screened for a history of sexual violence. The triggers with the highest intensity were arm and leg fixation during egg retrieval (66.2% and 66.8% of women respectively graded the trigger as 5/5). Past pregnancy was associated with a reduction in the intensity of triggers, but this was of small magnitude (5.8%). Although 65 women (59%) preferred a female physician to carry out fertility-related procedures, most women accepted the treating physician regardless of gender as long as the physician was trained in trauma-informed care.
Conclusion: Not all triggers related to infertility treatment can be completely avoided; however, a discussion with patients about what may pose a trigger and how to decrease the severity of that trigger is important.
{"title":"Fertility treatment after sexual trauma.","authors":"Ido Feferkorn, Assaf Goldberg, Meital Bonchek, Tatiana Beniar, Dana Taron-Amir, Judith Kadouch Kowalsky, Eytan Giladi Yacobi, Talya Shaulov, Mali Salmon-Divon, Foad Azem","doi":"10.1016/j.rbmo.2025.105022","DOIUrl":"10.1016/j.rbmo.2025.105022","url":null,"abstract":"<p><strong>Research question: </strong>What are the experiences, needs and preferences of women with a history of sexual trauma undergoing fertility treatment?</p><p><strong>Design: </strong>Women survivors of sexual violence who were previously referred for, underwent or were undergoing fertility treatment were invited to participate in an online survey. Respondents were asked about which screening tool they preferred to gather information about the history of sexual violence, and to rate the significance of specific triggers related to fertility treatment.</p><p><strong>Results: </strong>A total of 155 women responded to the survey. The preferred screening tool for a history of sexual violence was an intake form (76 women [63%]) followed by direct questioning (20 women [16.5%]). Only 11 women (9%) preferred not to be screened for a history of sexual violence. The triggers with the highest intensity were arm and leg fixation during egg retrieval (66.2% and 66.8% of women respectively graded the trigger as 5/5). Past pregnancy was associated with a reduction in the intensity of triggers, but this was of small magnitude (5.8%). Although 65 women (59%) preferred a female physician to carry out fertility-related procedures, most women accepted the treating physician regardless of gender as long as the physician was trained in trauma-informed care.</p><p><strong>Conclusion: </strong>Not all triggers related to infertility treatment can be completely avoided; however, a discussion with patients about what may pose a trigger and how to decrease the severity of that trigger is important.</p>","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"51 4","pages":"105022"},"PeriodicalIF":3.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Digital twins - the term for virtual representations of biological systems - are emerging as promising tools in reproductive medicine. They offer personalized simulations for optimizing fertility, assisted reproductive technology (ART) and pregnancy outcomes. However, their use remains limited and fragmented across diverse applications. A systematic search was conducted in PubMed, EMBASE, Scopus and IEEE Xplore up to July 2025 for this review of the current evidence on digital twins in fertility, ART and pregnancy, identifying applications, outcomes, challenges and future prospects. Original studies that applied digital twins to fertility, ART or pregnancy in human or in-silico models were included in this review. Eight original studies were included, complemented by nine mechanistic or conceptual works. Applications encompassed embryo selection, IVF procedure modelling, placental physiology, pregnancy pharmacokinetics, and intrapartum monitoring. Most studies were predictive or descriptive in nature, static or batch-coupled, and at early stages of validation. Risk of bias ranged from moderate to high due to study design and external validity concerns. Only two studies fulfilled strict digital twin criteria, and the exclusion of borderline studies did not change the overall conclusions. Digital twins hold substantial promise for personalized reproductive care. However, their clinical utility remains largely theoretical. Future work must improve modelling accuracy, data integration and ethical implementation to unlock their full potential.
{"title":"Digital twins in fertility, assisted reproductive technology and pregnancy: a systematic review.","authors":"Alexandre Vallée, Gaby Moawad, Anis Feki, Jean-Marc Ayoubi","doi":"10.1016/j.rbmo.2025.105281","DOIUrl":"https://doi.org/10.1016/j.rbmo.2025.105281","url":null,"abstract":"<p><p>Digital twins - the term for virtual representations of biological systems - are emerging as promising tools in reproductive medicine. They offer personalized simulations for optimizing fertility, assisted reproductive technology (ART) and pregnancy outcomes. However, their use remains limited and fragmented across diverse applications. A systematic search was conducted in PubMed, EMBASE, Scopus and IEEE Xplore up to July 2025 for this review of the current evidence on digital twins in fertility, ART and pregnancy, identifying applications, outcomes, challenges and future prospects. Original studies that applied digital twins to fertility, ART or pregnancy in human or in-silico models were included in this review. Eight original studies were included, complemented by nine mechanistic or conceptual works. Applications encompassed embryo selection, IVF procedure modelling, placental physiology, pregnancy pharmacokinetics, and intrapartum monitoring. Most studies were predictive or descriptive in nature, static or batch-coupled, and at early stages of validation. Risk of bias ranged from moderate to high due to study design and external validity concerns. Only two studies fulfilled strict digital twin criteria, and the exclusion of borderline studies did not change the overall conclusions. Digital twins hold substantial promise for personalized reproductive care. However, their clinical utility remains largely theoretical. Future work must improve modelling accuracy, data integration and ethical implementation to unlock their full potential.</p>","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"52 3","pages":"105281"},"PeriodicalIF":3.5,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146182029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-26DOI: 10.1016/j.rbmo.2025.105270
Enrico Papaleo, Antonio Quartucci, Mara Zanirato, Daria Marzanati, Valeria Stella Vanni, Edoardo Delfanti, Giulia Bertapelle, Massimo Candiani
Research question: Does the long-acting stimulation protocol with corifollitropin alfa (CFA) followed by daily low-dose recombinant FSH (r-FSH) reduce the risk of premature progesterone elevation (PPE) in women with low ovarian reserve compared with daily high-dose r-FSH?
Design: This randomized controlled trial, conducted from February 2022 to May 2024, enrolled 110 patients who met the Bologna criteria for poor ovarian responders. Participants were randomized into two groups: the intervention group received long-acting CFA followed by daily 150 IU r-FSH from day 8; and the control group received daily 300 IU r-FSH. The primary outcome was the proportion of patients with progesterone ≥1.1 ng/ml on the day of human chorionic gonadotrophin trigger. Secondary outcomes included number of retrieved oocytes, fertilization rate, fresh embryo transfer rate, and pregnancy rate.
Results: A significantly lower rate of PPE was observed in the CFA group compared with the control group [2/56 (3.6%) versus 12/54 (22.2%), respectively]. CFA stimulation was associated with an 89% reduction in the odds of PPE (OR 0.11, 95% CI 0.02-0.55; P = 0.007). Fresh embryo transfer was achieved in 34/52 (65%) patients in the CFA group versus 21/48 (44%) patients in the control group (P = 0.04).
Conclusions: Ovarian stimulation with long-acting CFA plus daily 150 IU r-FSH significantly reduced the risk of PPE and increased the feasibility of fresh embryo transfer in patients with low ovarian reserve. This strategy may offer a better approach for managing PPE, and may improve overall IVF success for this specific patient population.
研究问题:与每日高剂量的r-FSH相比,口服促孕激素(CFA)和每日低剂量重组FSH (r-FSH)的长效刺激方案是否能降低卵巢储备能力低的女性早孕激素升高(PPE)的风险?设计:该随机对照试验于2022年2月至2024年5月进行,纳入了110名符合Bologna标准的卵巢不良反应患者。参与者被随机分为两组:干预组从第8天开始接受长效CFA,随后每日150 IU r-FSH;对照组每天给予300 IU的r-FSH。主要终点是人绒毛膜促性腺激素触发当天孕激素≥1.1 ng/ml的患者比例。次要结果包括卵母细胞数量、受精率、新鲜胚胎移植率和妊娠率。结果:CFA组PPE发生率明显低于对照组[2/56 (3.6%)vs . 12/54(22.2%)]。CFA刺激与PPE发生率降低89%相关(OR 0.11, 95% CI 0.02-0.55; P = 0.007)。CFA组34/52例(65%)患者实现了新鲜胚胎移植,对照组21/48例(44%)患者实现了新鲜胚胎移植(P = 0.04)。结论:卵巢刺激长效CFA加每日150 IU r-FSH可显著降低卵巢储备不足患者发生PPE的风险,提高新鲜胚胎移植的可行性。这种策略可能为管理PPE提供更好的方法,并可能提高这一特定患者群体的整体试管婴儿成功率。
{"title":"Risk of progesterone elevation in patients with low ovarian reserve using long-acting FSH IVF protocol: a randomized controlled trial.","authors":"Enrico Papaleo, Antonio Quartucci, Mara Zanirato, Daria Marzanati, Valeria Stella Vanni, Edoardo Delfanti, Giulia Bertapelle, Massimo Candiani","doi":"10.1016/j.rbmo.2025.105270","DOIUrl":"https://doi.org/10.1016/j.rbmo.2025.105270","url":null,"abstract":"<p><strong>Research question: </strong>Does the long-acting stimulation protocol with corifollitropin alfa (CFA) followed by daily low-dose recombinant FSH (r-FSH) reduce the risk of premature progesterone elevation (PPE) in women with low ovarian reserve compared with daily high-dose r-FSH?</p><p><strong>Design: </strong>This randomized controlled trial, conducted from February 2022 to May 2024, enrolled 110 patients who met the Bologna criteria for poor ovarian responders. Participants were randomized into two groups: the intervention group received long-acting CFA followed by daily 150 IU r-FSH from day 8; and the control group received daily 300 IU r-FSH. The primary outcome was the proportion of patients with progesterone ≥1.1 ng/ml on the day of human chorionic gonadotrophin trigger. Secondary outcomes included number of retrieved oocytes, fertilization rate, fresh embryo transfer rate, and pregnancy rate.</p><p><strong>Results: </strong>A significantly lower rate of PPE was observed in the CFA group compared with the control group [2/56 (3.6%) versus 12/54 (22.2%), respectively]. CFA stimulation was associated with an 89% reduction in the odds of PPE (OR 0.11, 95% CI 0.02-0.55; P = 0.007). Fresh embryo transfer was achieved in 34/52 (65%) patients in the CFA group versus 21/48 (44%) patients in the control group (P = 0.04).</p><p><strong>Conclusions: </strong>Ovarian stimulation with long-acting CFA plus daily 150 IU r-FSH significantly reduced the risk of PPE and increased the feasibility of fresh embryo transfer in patients with low ovarian reserve. This strategy may offer a better approach for managing PPE, and may improve overall IVF success for this specific patient population.</p>","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"52 3","pages":"105270"},"PeriodicalIF":3.5,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146119918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-26DOI: 10.1016/j.rbmo.2025.105277
Paul Pirtea , Baris Ata
The commonly used 7 mm threshold for endometrial thickness in assisted reproductive technology lacks strong evidence and stems from outdated data. Recent studies show that live birth outcomes are comparable even with linings of less than 7 mm, particularly when using euploid embryos. Measurement variability, confounding factors and differing clinical practices limit the reliability of endometrial thickness as a standalone predictor. While extremely thin linings may warrant further evaluation, rigid cut-off values are unjustified. Endometrial thickness should be integrated into a broader, individualized assessment rather than drive clinical decisions in isolation.
{"title":"The endometrium: is thickness all that counts?","authors":"Paul Pirtea , Baris Ata","doi":"10.1016/j.rbmo.2025.105277","DOIUrl":"10.1016/j.rbmo.2025.105277","url":null,"abstract":"<div><div>The commonly used 7 mm threshold for endometrial thickness in assisted reproductive technology lacks strong evidence and stems from outdated data. Recent studies show that live birth outcomes are comparable even with linings of less than 7 mm, particularly when using euploid embryos. Measurement variability, confounding factors and differing clinical practices limit the reliability of endometrial thickness as a standalone predictor. While extremely thin linings may warrant further evaluation, rigid cut-off values are unjustified. Endometrial thickness should be integrated into a broader, individualized assessment rather than drive clinical decisions in isolation.</div></div>","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"52 3","pages":"Article 105277"},"PeriodicalIF":3.5,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146038315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-26DOI: 10.1016/S1472-6483(25)00452-3
{"title":"Inside Front Cover - Affiliations and First page of TOC","authors":"","doi":"10.1016/S1472-6483(25)00452-3","DOIUrl":"10.1016/S1472-6483(25)00452-3","url":null,"abstract":"","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"51 4","pages":"Article 105245"},"PeriodicalIF":3.5,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145157649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-18DOI: 10.1016/j.rbmo.2025.105269
Stefano Palomba , Giuseppe Seminara , Antonio Aversa
Myo-inositol has gained widespread use in the management of infertility associated with polycystic ovary syndrome (PCOS), driven by its proposed role in improving insulin sensitivity and ovarian function. Despite its popularity in clinical practice, the evidence supporting myo-inositol’s efficacy in enhancing fertility outcomes remains limited and inconclusive. Current international and national guidelines do not endorse myo-inositol as a first-line treatment for PCOS-related infertility, either as monotherapy or in combination with ovulation induction agents. Even if early studies suggest potential benefits when used alongside clomiphene citrate or gonadotrophins, these findings are often outdated or misaligned with contemporary treatment protocols that favour letrozole and gonadotrophin-releasing hormone antagonist regimens. In the context of IVF, myo-inositol may reduce gonadotrophin requirements and improve some intermediate/secondary outcomes, although data on live births and long-term efficacy are lacking. This commentary critically evaluates the current literature on use of myo-inositol in PCOS fertility care, emphasizing the need for well-designed, adequately powered randomized controlled trials that reflect current clinical standards. Until stronger evidence is available, myo-inositol should not be routinely recommended in fertility protocols for PCOS but reserved for individualized cases within an evidence-based framework.
{"title":"Myo-inositol in reproductive management of women with PCOS: holy grail for medical practice or demon for scientific evidence?","authors":"Stefano Palomba , Giuseppe Seminara , Antonio Aversa","doi":"10.1016/j.rbmo.2025.105269","DOIUrl":"10.1016/j.rbmo.2025.105269","url":null,"abstract":"<div><div>Myo-inositol has gained widespread use in the management of infertility associated with polycystic ovary syndrome (PCOS), driven by its proposed role in improving insulin sensitivity and ovarian function. Despite its popularity in clinical practice, the evidence supporting myo-inositol’s efficacy in enhancing fertility outcomes remains limited and inconclusive. Current international and national guidelines do not endorse myo-inositol as a first-line treatment for PCOS-related infertility, either as monotherapy or in combination with ovulation induction agents. Even if early studies suggest potential benefits when used alongside clomiphene citrate or gonadotrophins, these findings are often outdated or misaligned with contemporary treatment protocols that favour letrozole and gonadotrophin-releasing hormone antagonist regimens. In the context of IVF, myo-inositol may reduce gonadotrophin requirements and improve some intermediate/secondary outcomes, although data on live births and long-term efficacy are lacking. This commentary critically evaluates the current literature on use of myo-inositol in PCOS fertility care, emphasizing the need for well-designed, adequately powered randomized controlled trials that reflect current clinical standards. Until stronger evidence is available, myo-inositol should not be routinely recommended in fertility protocols for PCOS but reserved for individualized cases within an evidence-based framework.</div></div>","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"52 2","pages":"Article 105269"},"PeriodicalIF":3.5,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145842368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}